According to the Arthritis Foundation (n.d.), “Adult-onset Still’s Disease is a type of arthritis with symptoms like fever, rash, and joint pain and was thought to be autoimmune or autoinflammatory”. As per the Orphanet (n.d.),” the estimated Adult-onset Still’s Disease prevalence is 1–9/100,000 population, and women are affected marginally more than men”. In addition, as per the statistics of the National Institute of Health (NIH) and Genetic and Rare Disease Information Center (GARD) (n.d.), “it has been estimated that about 1–4 people in one million have AoSD”.
Several therapies have been investigated in Adult-onset Still’s Disease Treatment Market, but none has proven effective consistently. Therefore, a variety of monotherapies and combinational therapies are used to treat the affected population. At present, the therapies in the Adult-onset Still’s Disease treatment market include Canakinumab (Novartis), Anakinra (Swedish Orphan Biopharma), and tocilizumab (Roche), while the upcoming therapies comprise CERC 007 (Cerecor) and Tadekinig Alfa (AB2 Bio). The launch of the emerging therapies in the Adult-Onset Still’s Disease Market is expected to change the treatment scenario for the affected population.
For more details, visit: Adult-Onset Still’s Disease Market Forecast